Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

NCT05702879 · clinicaltrials.gov ↗

UNKNOWN

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Ozanimod
DRUG: TNF Inhibitor
DRUG: Steroids
DRUG: Vedolizumab
DRUG: Ustekinumab

Sponsor

Insel Gruppe AG, University Hospital Bern

Collaborators

[object Object]